Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy
IRVINE, Calif., Aug. 9, 2022 /PRNewswire/ — Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: www.clinicaltrials.gov/ct2/show/NCT05211986 The open label […]
RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO
EDINBURGH, UK AND HOPKINTON, MA, 4 August 2022 – RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience (‘Lykan’), an innovative CDMO focused on cell-based therapies, today announce that they have entered into a business combination agreement to form a global leading innovative […]
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates. Through the alliance, TransCode and MD […]
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
NEW YORK, Aug. 1, 2022 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern […]
Why Are Stem Cells The Future Of Medicine
Why do stem cells matter for the future of medicine? NYSCF’s Senior Vice President of Research Scott Noggle, PhD dives into the basics of stem cell research and what it means for diseases like Alzheimer’s, macular degeneration, and ALS. Watch Dr. Noggle’s full presentation here.
Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study
PHOENIX, July 28, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company’s OvaStem® pilot study. The data shows significant efficacy of […]
First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
RESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) — The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and efficacy of its investigational wound care product, Dermacyte® Amniotic Wound Care Liquid, for the treatment of non-healing venous stasis ulcers. The Research […]
Cancer Genetics Expert Dr. Kelly Bolton Appointed to GoodCell’s Scientific Advisory Board
Waltham, MA, July 25, 2022 (GLOBE NEWSWIRE) — GoodCell, a Harvard Stem Cell Institute company, today appointed Kelly Bolton M.D., Ph.D., M.Phil., to its scientific advisory board. With a background in medical oncology and genetic epidemiology, Dr. Bolton focuses her research on the interplay between inherited genetic variation, environmental factors, and acquired mutations in shaping […]
Bionano Genomics Announces Publication of a New Study Using OGM to Investigate Chromosome Instability during Culture of Induced Pluripotent Stem Cells
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, during long-term culturing. This research provides scientific and practical support for the use of […]
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair
KNOXVILLE, TN, July 19, 2022 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Kelly Tseng, PhD, Associate Professor of Pathology and Lab Medicine, School of Life Sciences at the University of Nevada, Las Vegas (UNLV) to characterize the effects of Provectus’ pharmaceutical-grade rose bengal […]